Eisai has opened a new potent packaging facility at its EMEA Knowledge Centre in Hatfield, investing £8 million. The facility will handle the packaging of its investigational compound lenvatinib for the treatment of advanced thyroid cancer.    The 2,900m2 facility has hybrid packaging lines designed for highly potent, difficult-to-handle compounds, expanding the current Hatfield site by nearly 40%. The investment represents Eisai’s long-term global business structure to make the UK a key h...